TRCT
RLMD icon

Tower Research Capital (TRC)’s Relmada Therapeutics RLMD Stock Holding History

Tower Research Capital (TRC)’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,581
Closed -$3.18K – 5511
2025
Q3 		$3.18K Sell
1,581
-4,608
-74% -$4.42K ﹤0.01% 4538
2025
Q2 		$3.71K Buy
+6,189
New +$3.18K ﹤0.01% 4443
2025
Q1 		– Sell
-760
Closed -$396 – 5685
2024
Q4 		$396 Buy
+760
New +$1.85K ﹤0.01% 5288
2024
Q3 		– Sell
-2,754
Closed -$8.26K – 5935
2024
Q2 		$8.26K Sell
2,754
-7,002
-72% -$25.3K ﹤0.01% 4372
2024
Q1 		$45.4K Buy
9,756
+7,307
+298% +$35.2K ﹤0.01% 2350
2023
Q4 		$10.1K Buy
2,449
+739
+43% +$2.19K ﹤0.01% 4288
2023
Q3 		$5.13K Sell
1,710
-3,107
-65% -$9.23K ﹤0.01% 4756
2023
Q2 		$11.8K Buy
4,817
+198
+4% +$547 ﹤0.01% 3924
2023
Q1 		$10K Sell
4,619
-19,422
-81% -$67K ﹤0.01% 4400
2022
Q4 		$84K Buy
24,041
+23,189
+2,722% +$204K ﹤0.01% 1968
2022
Q3 		$32K Sell
852
-617
-42% -$17.1K ﹤0.01% 3556
2022
Q2 		$28K Buy
1,469
+1,261
+606% +$27.5K ﹤0.01% 3453
2022
Q1 		$6K Sell
208
-1,019
-83% -$21.1K ﹤0.01% 4917
2021
Q4 		$28K Buy
1,227
+546
+80% +$12.1K ﹤0.01% 3310
2021
Q3 		$18K Sell
681
-360
-35% -$9.64K ﹤0.01% 3834
2021
Q2 		$33K Sell
1,041
-757
-42% -$26.3K ﹤0.01% 3397
2021
Q1 		$63K Buy
1,798
+620
+53% +$21.7K ﹤0.01% 2933
2020
Q4 		$37K Sell
1,178
-11,104
-90% -$382K ﹤0.01% 3397
2020
Q3 		$462K Buy
12,282
+11,381
+1,263% +$440K 0.01% 1769
2020
Q2 		$40K Buy
+901
New +$38.1K ﹤0.01% 3235
2020
Q1 		– Sell
-2,143
Closed -$84K – 3763
2019
Q4 		$84K Buy
+2,143
New +$65.1K 0.01% 1043

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tower Research Capital (TRC)'s RLMD Position: Q4 2025 in Review

Tower Research Capital (TRC) sold out of Relmada Therapeutics (RLMD) in Q4 2025, closing a stake of 1,581 shares — an estimated $3.18K sold.

Tower Research Capital (TRC) first reported a position in RLMD in Q4 2019 and held it in 21 quarters. The position peaked at $462K in Q3 2020. 78 funds tracked by Wall St. Rank hold RLMD as of Q4 2025.

  • Tower Research Capital (TRC) reported no remaining Relmada Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 1,581 Relmada Therapeutics shares in Q4 2025, an estimated $3.18K.
  • Tower Research Capital (TRC) first reported a position in Relmada Therapeutics in Q4 2019 and held it in 21 quarters.
  • Tower Research Capital (TRC)'s Relmada Therapeutics position peaked at $462K in Q3 2020.
  • 78 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2025, filed 17 Feb 2026.